HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Endo News Roundup: Managing HbA1c & CV Risks

New studies highlight which T2DM meds help reduce CV risks and, for metformin failure, the benefits of early intervention & a promising drug combo.

T2DM patients who take gliptins or glitazones may have decreased risks of heart failure, cardiovascular disease, and all-cause mortality. Early intervention in T2DM patients who fail metformin monotherapy can lead to rapid attainment of HbA1c goals. Insulin glargine plus the glucose-lowering agent lixisenatide complement each other and lead to clinically meaningful HbA1c reductions in T2DM more than either drug alone.